Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction : microsimulation analysis of the 1999 nationwide french hospitals database.

Background— Women with acute myocardial infarction have a higher hospital mortality rate than men. This difference has been ascribed to their older age, more frequent comorbidities, and less frequent use of revascularization. The aim of this study is to assess these factors in relation to excess mortality in women. Methods and Results— All hospital admissions in France with a discharge diagnosis of acute myocardial infarction were extracted from the national payment database. Logistic regression on mortality was performed for age, comorbidities, and coronary interventions. Nonparametric microsimulation models estimated the percutaneous coronary intervention and mortality rates that women would experience if they were "treated like men." Data were analyzed from 74 389 patients hospitalized with acute myocardial infarction, 30.0% of whom were women. Women were older (75 versus 63 years of age; Pacute myocardial infarction gender; revascularization; mortality;

Retinal microvascularisation abnormalities and cardiovascular risk

SummaryThe progress of retinal imaging techniques has made retinal microvascular circulation easier to study. A number of observational studies were conducted to characterise the different abnormalities encountered and to determine the factors contributing to their onset. Three lesion groups were highlighted, including reduced arteriolar diameter, venular dilatation and retinopathy lesions. Retinal arteriolar narrowing signals the presence of hypertension (current or old) and the risk of hypertension onset. A genetic factor was implicated in this relationship. Venular dilatation and retinopathy correlate with the presence of diabetes, obesity and metabolic disorders. This association appears to be mediated partly by the presence of endothelial dysfunction and inflammation. The relationship between these abnormalities and cardiovascular risk was also studied in a number of longitudinal studies: the presence of retinal microvascular abnormalities is related with an increased risk of cardiovascular morbidity and mortality predominantly in individuals under the age of 75. More specifically, retinopathy is correlated with the presence of cerebral white matter lesions detected by MRI, an increased stroke risk and deterioration in cognitive function. On the cardiovascular level, a correlation was demonstrated between diminished coronary reserve, increased coronary calcifications observed by CT scan, coronary morbidity and mortality, and risk of heart failure. New techniques of retinal imaging, such as laser Doppler flowmetry, are still undergoing assessment and will help further to clarify these correlations

Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study

Aim: The aim of this study was to determine the impact of emergent bradycardia and atrial fibrillation (AF) on cardiovascular outcomes in 19 083 patients with stable coronary artery disease (CAD) receiving ivabradine or placebo (SIGNIFY, Study assessInG the morbidity–mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease). Methods and results: Emergent bradycardia (resting heart rate <50 b.p.m. on 12-lead electrocardiogram) with ivabradine was reported in 3572 patients (37.4%) overall, and in 2242 (37.2%) patients with Canadian Cardiovascular Society (CCS) class ≥2 angina. There was no difference in outcomes over the course of the study in ivabradine-treated patients with and without emergent bradycardia in the whole population (2.5 vs. 2.9% per year, respectively, for primary composite endpoint of cardiovascular death or non-fatal myocardial infarction) or in the angina subgroup (2.5 vs. 3.2% per year). Neither was there an increase in the rate of primary endpoint after emergent bradycardia was recorded compared with those without emergent bradycardia. There were 754 cases of emergent AF on treatment (2.2% per year ivabradine vs. 1.5% per year placebo) and 469 in the patients with angina (2.2 vs. 1.5% per year). While outcomes occurred more frequently in patients in whom emergent AF had been recorded, there was no treatment–placebo difference in outcomes, including stroke, and no difference in treatment effect in patients with limiting angina. Conclusion: Both in the overall population as well as in the angina subset, bradycardia was common in ivabradine-treated patients, but did not appear to impact outcomes. Emergent AF was relatively rare and did not appear to have an impact on outcomes relative to placebo

Quality of life with ivabradine in patients with angina pectoris

Background—To explore the effect of ivabradine on angina-related quality of life (QoL) in patients participating in the Study Assessing the Morbidity–Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery Disease (SIGNIFY) QoL substudy. Methods and Results—QoL was evaluated in a prespecified subgroup of SIGNIFY patients with angina (Canadian Cardiovascular Society class score, ≥2 at baseline) using the Seattle Angina Questionnaire and a generic visual analogue scale on health status. Data were available for 4187 patients (2084 ivabradine and 2103 placebo). There were improvements in QoL in both treatment groups. The primary outcome of change in physical limitation score at 12 months was 4.56 points for ivabradine versus 3.40 points for placebo (E, 0.96; 95% confidence interval, –0.14 to 2.05; P=0.085). The ivabradine−placebo difference in physical limitation score was significant at 6 months (P=0.048). At 12 months, the visual analogue scale and the other Seattle Angina Questionnaire dimensions were higher among ivabradine-treated patients, notably angina frequency (P<0.001) and disease perception (P=0.006). Patients with the worst QoL at baseline (ie, those in the lowest tertile of score) had the best improvement in QoL for 12 months, with improvements in physical limitation and a significant reduction in angina frequency (P=0.034). The effect on QoL was maintained over the study duration, and ivabradine patients had better scores on angina frequency at every visit to 36 months. Conclusions—Treatment with ivabradine did not affect the primary outcome of change in physical limitation score at 12 months. It did produce consistent improvements in other self-reported QoL parameters related to angina pectoris, notably in terms of angina frequency and disease perception

Gender Differences in Hospital Mortality and Use of Percutaneous Coronary Intervention in Acute Myocardial Infarction. Microsimulation Analysis of the 1999 Nationwide French Hospitals Database

The difference in mortality rate between men and women with acute myocardial infarction is due largely to the different age structure of these populations. However, age-adjusted hospital mortality was higher for women and was associated with a lower rate of percutaneous coronary intervention. Simulations suggest that women would derive benefit from more frequent use of percutaneous coronary intervention, although these procedures appear less protective in women than in men

Direct-acting Anticoagulants in Chronic Coronary Syndromes

Direct-acting oral anticoagulants (DOACs) are easier to use, safer than and as effective as vitamin K antagonists (VKA) in the treatment of non-valvular AF (NVAF). Because of their favourable safety profile and easier use than VKAs, DOACs as anti-thrombotic therapy may have a role in the management of chronic coronary syndromes (CCS). To date, few studies have evaluated DOACs in this setting. Initial studies have focused on patients receiving DOACs for NVAF undergoing acute or elective percutaneous coronary intervention who additionally require dual antiplatelet therapy (DAPT). Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor compared with a VKA regimen was associated with a reduction of bleedings (HR 0.59; 95% CI [0.47–0.76]; p<0.001). Rivaroxaban 2.5 mg twice daily plus DAPT up to 12 months followed by rivaroxaban 15 mg once daily plus P2Y12 inhibitor showed similar results. Dabigatran 110 mg twice daily plus a P2Y12 inhibitor versus a VKA regimen was associated with a reduction of bleedings (HR 0.52; 95% CI [0.42–0.63]; p<0.001), after a mean follow-up of 14 months. A dabigatran 150 mg regimen showed similar results. Apixaban 5 mg twice daily plus a P2Y12 inhibitor versus a VKA regimen confirmed at 6 months the safety of DOACs with a reduction of bleedings (HR 0.69; 95% CI [0.58–0.81]; p<0.001 for non-inferiority and superiority). Edoxaban 60 mg once daily plus a P2Y12 inhibitor was non-inferior to a VKA regimen on bleeding outcomes (major bleeding or non-major clinically relevant non-major bleeding) after a 12-month follow-up (HR 0.83; 95% CI [0.65–1.05]; p=0.001 for non-inferiority; p=0.1154 for superiority). Meta-analysis of these four trials confirmed the safety of DOACs regarding bleeding outcomes, but showed a trend toward stent thrombosis for dual antithrombotic therapy using DOACs versus triple antithrombotic therapy using VKAs. DOACs may show promise in the management of high-risk patients with chronic coronary syndromes. In these patients, rivaroxaban 2.5 mg twice daily in addition to aspirin was shown to reduce the composite outcome of cardiovascular death, stroke or MI compared to aspirin alone (HR 0.76; 95% CI [0.66–0.86]; p<0.001). All-cause death, cardiovascular death and stroke were also significantly lower. This benefit was at the cost of an increase in non-fatal bleeding

Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry

Background: To use CLARIFY, a prospective registry of patients with stable CAD (45 countries), to explore heart rate (HR) control and beta-blocker use.&lt;p&gt;&lt;/p&gt; Methods: We analyzed the CLARIFY population according to beta-blocker use via descriptive statistics with Pearson's χ2 test for comparisons, as well as a multivariable stepwise model.&lt;p&gt;&lt;/p&gt; Results: Data on beta-blocker use was available for 32,914 patients, in whom HR was 68 ± 11 bpm; patients with angina, previous myocardial infarction, and heart failure had HRs of 69 ± 12, 68 ± 11, and 70 ± 12 bpm, respectively. 75% of these patients were receiving beta-blockers. Bisoprolol (34%), metoprolol tartrate (16%) or succinate (13%), atenolol (15%), and carvedilol (12%) were mostly used; mean dosages were 49%, 76%, 35%, 53%, and 45% of maximum doses, respectively. Patients aged &#60; 65 years were more likely to receive beta-blockers than patients &#8805; 75 years (P &#60; 0.0001). Gender had no effect. Subjects with HR &#8804; 60 bpm were more likely to be on beta-blockers than patients with HR &#8805; 70 bpm (P &#60; 0.0001). Patients with angina, previous myocardial infarction, heart failure, and hypertension were more frequently receiving beta-blockers (all P &#60; 0.0001), and those with PAD and asthma/COPD less frequently (both P &#60; 0.0001). Beta-blocker use varied according to geographical region (from 87% to 67%).&lt;p&gt;&lt;/p&gt; Conclusions: Three-quarters of patients with stable CAD receive beta-blockers. Even so, HR is insufficiently controlled in many patients, despite recent guidelines for the management of CAD. There is still much room for improvement in HR control in the management of stable CAD

957-108 Does Reperfusion Induced by Angioplasty Confer the Same Benefit as Thrombolysis in Terms of Late Potentials?

Angioplasty or thrombolysis (T) during acute myocardial infarction (MI) are two effective methods for achieving reperfusion, but whether reperfusion induced by angioplasty confers the same protection against the presence of late potentials on signal-averaged electrocardiography (SAE) as that induced by T remains debated. We studied retrospectively 102 consecutive Pts with successful reperfusion (TIMI grade 3 patency in acute phase), obtained by T, primary angioplasty (P), or rescue angioplasty (R) during the first 6 hours of MI. T Pts all had angiography at 90min to prove reperfusion. All had SAE &gt;6 days later. Late potentials were defined as, ≥2 of the following criteria: QRS &gt;120msec, RMS40 &lt;20μV, LAS&gt; 38msec. Results are (mean±SD):TPRPnumber of Pts354027Age (years)59.9±1160.5±1453±13&lt;0.04% males868593NS% anterior545846NSTime to treatment (min)169±72212±79171±76NSTime to reperfusion (min)285±75*261±90280±98NSEjection fraction°(%)53±845±1546±14NS% Late potentials431011&lt;0.001*time to 90min angiography with proven reperfusion°radionuclide left ventricular ejection fraction at dischargeThus, after MI, the prevalence of late potentials appears lower when acute reperfusion is obtained by angioplasty rather than by thrombolysis. This difference does not appear related to differences in time to treatment, time to reperfusion, left ventricular function or other patient characteristics

The reply

No abstract available